 Allergan, an AbbVie Inc NYSE: ABBV company, announced topline data from Phase 3 VIRGO trial evaluating Vuity pilocarpine HCl ophthalmic solution 1.25 in adults with presbyopia, age-related blurry near vision. The study met its primary efficacy endpoint, improving near vision. 